Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 10, 2024, titled "Zydus Lifesciences announces completion of Phase II(a) clinical trial of Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with Amyotrophic Lateral Sclerosis (ALS)".
Press Release Sep 10 2024
Filed with NSE · · 4 pages · English
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Zydus receives final approval from USFDA for Scopolamine Transdermal System 1 mg/3 days
- Press Release Aug 30 2024
- Press Release Aug 27 2024
- Press Release Aug 23 2024
- Press Release Aug 09 2024
Later from Zydus Lifesciences
- Press Release Sep 13 2024
- Press Release Sep 27 2024
- Press Release Sep 28 2024
- Press Release Oct 01 2024
- Press Release Oct 02 2024
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences